The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Levodopa/Carbidopa/Entacapone Orion levodopa;carbidopa;entacapone | Orion Corporation | Parkinson Disease | 🇪🇺 EU 2011-08-23 | Order → |
| Trajenta linagliptin | Boehringer Ingelheim International GmbH | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2011-08-23 | Order → |
| Entacapone Orion entacapone | Orion Corporation | Parkinson Disease | 🇪🇺 EU 2011-08-18 | Order → |
| Ibandronic Acid Sandoz ibandronic acid Generic | Sandoz GmbH | Breast Neoplasms; Neoplasm Metastasis; Fractures, Bone | 🇪🇺 EU 2011-07-26 | Order → |
| Zoely nomegestrol;estradiol | Theramex Ireland Limited | Contraception | 🇪🇺 EU 2011-07-26 | Order → |
| Fampyra fampridine | Merz Therapeutics GmbH | Multiple Sclerosis | 🇪🇺 EU 2011-07-20 | Order → |
| Tobi Podhaler tobramycin | Viatris Healthcare Limited | Cystic Fibrosis; Respiratory Tract Infections | 🇪🇺 EU 2011-07-20 | Order → |
| Victrelis boceprevir | Merck Sharp Dohme Ltd | Hepatitis C, Chronic | 🇪🇺 EU 2011-07-18 | Order → |
| Benlysta belimumab | GlaxoSmithKline (Ireland) Limited | Lupus Erythematosus, Systemic | 🇪🇺 EU 2011-07-13 | Order → |
| Temozolomide Sun temozolomide Generic | Sun Pharmaceutical Industries Europe B.V. | Glioma | 🇪🇺 EU 2011-07-13 | Order → |
| Xgeva denosumab | Amgen Europe B.V. | Giant Cell Tumor of Bone; Neoplasms, Bone Tissue | 🇪🇺 EU 2011-07-13 | Order → |
| Yervoy ipilimumab | Bristol-Myers Squibb Pharma EEIG | Melanoma; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung; Mesothelioma, Malignant; Colorectal Neoplasms | 🇪🇺 EU 2011-07-13 | Order → |
| Sprimeo HCT aliskiren;hydrochlorothiazide | Novartis Europharm Ltd. | Hypertension | 🇪🇺 EU 2011-06-23 | Order → |
| Bydureon exenatide | AstraZeneca AB | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2011-06-17 | Order → |
| Nulojix belatacept | Bristol-Myers Squibb Pharma EEIG | Graft Rejection; Kidney Transplantation | 🇪🇺 EU 2011-06-17 | Order → |
| Clopidogrel Teva Pharma B.V. clopidogrel Generic | Teva Pharma B.V. | Peripheral Vascular Diseases; Acute Coronary Syndrome; Myocardial Infarction; Stroke | 🇪🇺 EU 2011-06-16 | Order → |
| Leganto rotigotine | UCB Pharma S.A. | Restless Legs Syndrome; Parkinson Disease | 🇪🇺 EU 2011-06-16 | Order → |
| Rivastigmine Actavis rivastigmine Generic | Actavis Group PTC ehf | Dementia; Alzheimer Disease; Parkinson Disease | 🇪🇺 EU 2011-06-16 | Order → |
| Cinryze C1 inhibitor (human) | Takeda Manufacturing Austria AG | Angioedemas, Hereditary | 🇪🇺 EU 2011-06-15 | Order → |
| Eliquis apixaban | Bristol-Myers Squibb / Pfizer EEIG | Arthroplasty; Venous Thromboembolism | 🇪🇺 EU 2011-05-18 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.